Mobile

Pharmacokinetics, pharmacodynamics and safety of DEB025/alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 patients who have previously failed interferon therapy...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003751-38

Pharmacokinetics, pharmacodynamics and safety of DEB025/alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 patients who have previously failed interferon therapy or are intolerant or unable to take interferon

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate pharmacodynamics, pharmacokinetic between 2 treatment groups receiving different doses of DEB025 in combination with RBV

Critère d'inclusion

  • Chronic hepatitis C

Liens